XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock
XOMAOStock
$25.00+48.01%52W
Market Cap$710.15M
P/E22.39x
Div yield—
Beta0.88
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)41.97%
Price vs S&P 500 (4W)-4.88%
VGM Score49.20
Market Capitalization$710.15M
P/E Ratio (Annual)22.39x
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.09
3.80
3.89
3.89
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XOMAOXOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | D | C | B | $25.00 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires the future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical and biotechnology companies. This non-dilutive funding model enables biotech firms to advance their development programs without diluting shareholder equity. The company operates across Switzerland, the United States, Europe, Asia Pacific, and other key markets.